Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Major Program(s) or Research Group(s)

  • Gastrointestinal and Other Cancers
  • Phase 0/I/II Cancer Prevention Clinical Trials Program

Sponsor

National Cancer Institute (NCI)

Status

Active, not recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT02961374

This phase II trial studies the side effects of erlotinib hydrochloride (350 mg po once
weekly for up to 6 months) and how well it works in reducing duodenal polyp burden in
patients with familial adenomatous polyposis at risk of developing colon cancer. Erlotinib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.

Intervention

Erlotinib, Erlotinib Hydrochloride

Condition

Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis

Investigators

Niloy J Samadder

See list of participating sites